CureVac NV (CVAC)
2.70
-0.04
(-1.64%)
USD |
NASDAQ |
Nov 14, 12:13
CureVac PE Ratio (Forward)
PE Ratio (Forward) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio (Forward) Data
| Date | Value |
|---|---|
| November 13, 2024 | -- |
| November 12, 2024 | -- |
| November 11, 2024 | -- |
| November 08, 2024 | -- |
| November 07, 2024 | -- |
| November 06, 2024 | -- |
| November 05, 2024 | -- |
| November 04, 2024 | -- |
| November 01, 2024 | -- |
| October 31, 2024 | -- |
| October 30, 2024 | -- |
| October 29, 2024 | -- |
| October 28, 2024 | -- |
| October 25, 2024 | -- |
| October 24, 2024 | -- |
| October 23, 2024 | -- |
| October 22, 2024 | -- |
| October 21, 2024 | -- |
| October 18, 2024 | -- |
| October 17, 2024 | -- |
| October 16, 2024 | -- |
| October 15, 2024 | -- |
| October 14, 2024 | -- |
| October 11, 2024 | -- |
| October 10, 2024 | -- |
| Date | Value |
|---|---|
| October 09, 2024 | -- |
| October 08, 2024 | -- |
| October 07, 2024 | -- |
| October 04, 2024 | -- |
| October 03, 2024 | -- |
| October 02, 2024 | -- |
| October 01, 2024 | -- |
| September 30, 2024 | -- |
| September 27, 2024 | -- |
| September 26, 2024 | -- |
| September 25, 2024 | -- |
| September 24, 2024 | -- |
| September 23, 2024 | -- |
| September 20, 2024 | -- |
| September 19, 2024 | -- |
| September 18, 2024 | -- |
| September 17, 2024 | -- |
| September 16, 2024 | -- |
| September 13, 2024 | -- |
| September 12, 2024 | -- |
| September 11, 2024 | -- |
| September 10, 2024 | -- |
| September 09, 2024 | -- |
| September 06, 2024 | -- |
| September 05, 2024 | -- |
Forward PE Ratio Definition
The Forward Price to Earnings (PE) Ratio is similar to the price to earnings ratio. The regular P/E ratio is a current stock price over its earnings per share. The forward P/E ratio is a current stock's price over its "predicted" earnings per share. If the forward P/E ratio is higher than the current P/E ratio, it indicates decreased expected earnings.
PE Ratio (Forward) Range, Past 5 Years
PE Ratio (Forward) Benchmarks
| BioNTech SE | -- |
| Bayer AG | Upgrade |
| Affimed NV | -- |
| InflaRx NV | -- |
| Immatics NV | -- |